TabletsClinical Overview
Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Oncology: Take orally 10 mg once daily with water, consistently with or without food. Transplant: Take 0.75 mg twice daily with therapeutic drug monitoring. Swallow tablets whole; do NOT chew or crush. Prophylactic alcohol-free dexamethasone mouthwash is recommended to prevent stomatitis.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Aphthous stomatitis / mouth ulceration (occurs in >60%), rash, fatigue, diarrhea, hyperglycemia, hyperlipidemia, infections, anemia. Rare/Severe: Non-infectious pneumonitis / interstitial lung disease, severe infections, and acute renal failure.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Non-infectious pneumonitis is a class effect; monitor for cough or dyspnea and interrupt therapy if grade 2+ pneumonitis occurs. High incidence of stomatitis; manage with steroid mouthwashes. Monitor fasting blood glucose and lipid panel routinely. Substrate of CYP3A4.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.
Everolimus Tablets 0.25 mg
Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.
Everolimus Tablets 0.5 mg
Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.
Everolimus Tablets 10 mg
Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.